Cargando…

Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice

Non-alcoholic fatty liver disease (NAFLD) has been considered to be one of the most common chronic liver diseases. However, no validated pharmacological therapies have been officially proved in clinic due to its complex pathogenesis. The purpose of this study was to examine the protective effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Mingjuan, Zhang, Rong, Wang, Yongling, Mao, Ziming, Wu, Jing, Guo, Huaqi, Zhang, Kaiwen, Jing, Yu, Zhang, Caoxu, Song, Huaidong, Chen, Xia, Wei, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443665/
https://www.ncbi.nlm.nih.gov/pubmed/36071929
http://dx.doi.org/10.3389/fnut.2022.983450
_version_ 1784783037026795520
author Liao, Mingjuan
Zhang, Rong
Wang, Yongling
Mao, Ziming
Wu, Jing
Guo, Huaqi
Zhang, Kaiwen
Jing, Yu
Zhang, Caoxu
Song, Huaidong
Chen, Xia
Wei, Gang
author_facet Liao, Mingjuan
Zhang, Rong
Wang, Yongling
Mao, Ziming
Wu, Jing
Guo, Huaqi
Zhang, Kaiwen
Jing, Yu
Zhang, Caoxu
Song, Huaidong
Chen, Xia
Wei, Gang
author_sort Liao, Mingjuan
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) has been considered to be one of the most common chronic liver diseases. However, no validated pharmacological therapies have been officially proved in clinic due to its complex pathogenesis. The purpose of this study was to examine the protective effects of Corilagin (referred to Cori) against NAFLD in mice under a high fat diet (HFD) condition. Mice were fed either a normal control diet (NCD) or HFD with or without Cori (5 or 10 mg/kg body weight) for 15 weeks. In our results, Cori treatment significantly attenuated HFD-induced hepatic steatosis, high NAFLD activity score (NAD) and liver injury. Consistently, Cori treatment remarkably alleviated HFD-induced hepatic lipid accumulation (e.g., triglycerides (TG) and total cholesterol (TC) contents in liver), and improved plasma lipid concentrations (e.g., plasma TG, TC, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c)). Moreover, Cori treatment ameliorated NAFLD associated metabolic disorders such as glucose intolerance and insulin resistance in HFD-fed mice. Additionally, Cori treatment dramatically changed HFD-induced liver gene expression profiles, and identified overlapped differentially expressed genes (DEGs) between NCD vs. HFD group and HFD vs. HCR (high fat diet plus treatment with Cori) group. With these DEGs, we observed a marked enrichment of Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, which were closely associated with the metabolic balance in liver. Particularly, we found several potential hub proteins against NAFLD development with analyses of protein-protein interaction (PPI) network and qPCR assays. Collectively, our results revealed the important protective effects of Cori against the progress of NAFLD, which was probably mediated through improving dysregulated lipid metabolism and insulin resistance in HFD-fed mice. Additionally, Cori-dependent overlapped DEGs might serve as a featured NAFLD-associated gene expression signature for the diagnosis, treatment, as well as drug discovery and development of NAFLD in the near future.
format Online
Article
Text
id pubmed-9443665
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94436652022-09-06 Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice Liao, Mingjuan Zhang, Rong Wang, Yongling Mao, Ziming Wu, Jing Guo, Huaqi Zhang, Kaiwen Jing, Yu Zhang, Caoxu Song, Huaidong Chen, Xia Wei, Gang Front Nutr Nutrition Non-alcoholic fatty liver disease (NAFLD) has been considered to be one of the most common chronic liver diseases. However, no validated pharmacological therapies have been officially proved in clinic due to its complex pathogenesis. The purpose of this study was to examine the protective effects of Corilagin (referred to Cori) against NAFLD in mice under a high fat diet (HFD) condition. Mice were fed either a normal control diet (NCD) or HFD with or without Cori (5 or 10 mg/kg body weight) for 15 weeks. In our results, Cori treatment significantly attenuated HFD-induced hepatic steatosis, high NAFLD activity score (NAD) and liver injury. Consistently, Cori treatment remarkably alleviated HFD-induced hepatic lipid accumulation (e.g., triglycerides (TG) and total cholesterol (TC) contents in liver), and improved plasma lipid concentrations (e.g., plasma TG, TC, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c)). Moreover, Cori treatment ameliorated NAFLD associated metabolic disorders such as glucose intolerance and insulin resistance in HFD-fed mice. Additionally, Cori treatment dramatically changed HFD-induced liver gene expression profiles, and identified overlapped differentially expressed genes (DEGs) between NCD vs. HFD group and HFD vs. HCR (high fat diet plus treatment with Cori) group. With these DEGs, we observed a marked enrichment of Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, which were closely associated with the metabolic balance in liver. Particularly, we found several potential hub proteins against NAFLD development with analyses of protein-protein interaction (PPI) network and qPCR assays. Collectively, our results revealed the important protective effects of Cori against the progress of NAFLD, which was probably mediated through improving dysregulated lipid metabolism and insulin resistance in HFD-fed mice. Additionally, Cori-dependent overlapped DEGs might serve as a featured NAFLD-associated gene expression signature for the diagnosis, treatment, as well as drug discovery and development of NAFLD in the near future. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9443665/ /pubmed/36071929 http://dx.doi.org/10.3389/fnut.2022.983450 Text en Copyright © 2022 Liao, Zhang, Wang, Mao, Wu, Guo, Zhang, Jing, Zhang, Song, Chen and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Liao, Mingjuan
Zhang, Rong
Wang, Yongling
Mao, Ziming
Wu, Jing
Guo, Huaqi
Zhang, Kaiwen
Jing, Yu
Zhang, Caoxu
Song, Huaidong
Chen, Xia
Wei, Gang
Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
title Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
title_full Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
title_fullStr Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
title_full_unstemmed Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
title_short Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
title_sort corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443665/
https://www.ncbi.nlm.nih.gov/pubmed/36071929
http://dx.doi.org/10.3389/fnut.2022.983450
work_keys_str_mv AT liaomingjuan corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT zhangrong corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT wangyongling corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT maoziming corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT wujing corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT guohuaqi corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT zhangkaiwen corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT jingyu corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT zhangcaoxu corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT songhuaidong corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT chenxia corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice
AT weigang corilaginpreventsnonalcoholicfattyliverdiseaseviaimprovinglipidmetabolismandglucosehomeostasisinhighfatdietfedmice